Evidence map›Paper›PMID 42013449›Full record

ArticleJournal of chemical information and modeling2026

Free Energy and Flexibility Analysis of Autoinhibited Human BRAF.

Jeremy O B Tempkin, Fikret Aydin, Sebnem Essiz, Yue Yang, Timothy S Carpenter, David E Durrant, Deborah K Morrison, Helgi I Ingólfsson, Frederick H Streitz, Dwight V Nissely and 2 more

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jeremy O B TempkinPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.ORCID 0000-0002-1602-6649
Fikret AydinPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.ORCID 0000-0003-3237-8043
Sebnem EssizFaculty of Natural Sciences and Engineering, Department of Molecular Biology and Genetics, Kadir Has University, Fatih 34083 Istanbul, Turkey.
Yue YangPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.
Timothy S CarpenterPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.ORCID 0000-0001-7848-9983
David E DurrantLaboratory of Cell and Developmental Signaling, Center for Cancer Research (CCR), National Cancer Institute (NCI), Frederick, Maryland 21702, United States.
Deborah K MorrisonLaboratory of Cell and Developmental Signaling, Center for Cancer Research (CCR), National Cancer Institute (NCI), Frederick, Maryland 21702, United States.
Helgi I IngólfssonPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.ORCID 0000-0002-7613-9143
Frederick H StreitzComputing Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.ORCID 0000-0003-0924-037X
Dwight V NisselyNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.ORCID 0000-0001-7523-116X
Felice C LightstonePhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.
Xiaohua ZhangPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94550, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The RAF serine/threonine protein kinases function as direct effectors of RAS in the intracellular transmission of extracellular growth signals, and they are key targets for drug discovery, given the high incidence of oncogenic mutations in RAF and other components of this signaling pathway. In its inactive state, RAF is held in an autoinhibited conformation in the cytosol through a combination of intramolecular interactions and binding to a regulatory 14-3-3 protein dimer. Activation of RAF is initiated by its interaction with membrane-localized GTP-bound RAS, which induces conformational changes that release RAF from its autoinhibited state. However, the molecular mechanisms governing RAF activation remain incomplete, largely due to the challenges in experimentally capturing the intermediate conformational states in this process. To address this gap, we developed a comprehensive all-atom model of BRAF based on existing cryo-EM structures. Using this model, we performed extensive molecular dynamics simulations to evaluate the stability and free energy landscape of autoinhibited BRAF in solution. Our analysis reveals conformational flexibility within the autoinhibited complex, suggesting that this dynamic behavior may play a role in facilitating BRAF activation upon engagement with the membrane-bound RAS.

Indexed as

Molecular Dynamics SimulationProto-Oncogene Proteins B-rafHumansProtein ConformationThermodynamicsBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID42013449
PMCPMC13169344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.